Functional Genetic Polymorphisms in the Aromatase GeneCYP19Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors
Authors:
- Liewei WangLWLiewei Wang
- Katarzyna A. EllsworthKEKatarzyna A. Ellsworth
- Irene MoonIMIrene Moon
- Linda L. PelleymounterLPLinda L. Pelleymounter
- Bruce W. EckloffBEBruce W. Eckloff
- Yvette N. MartinYMYvette N. Martin
- Brooke L. FridleyBFBrooke L. Fridley
- Gregory D. JenkinsGJGregory D. Jenkins
- Anthony BatzlerABAnthony Batzler
- Vera J. SumanVSVera J. Suman
- Saranya RaviSRSaranya Ravi
- J. Michael DixonJDJ. Michael Dixon
- 1 January 2010
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 70 (1) , 319-328
Abstract
Aromatase (CYP19) is a critical enzyme in estrogen biosynthesis and aromatase inhibitors (AI) are employed widely for endocrine therapy in postmenopausal women with breast cancer. We hypothesized that single nucleotide polymorphisms (SNPs) in the CYP19 gene may alter the effectiveness of AI therapy in the neoadjuvant setting. Genomic DNA was obtained for sequencing from 52 women pre-AI and post-AI treatment in this setting. Additionally, genomic DNA obtained from 82 samples of breast cancer and 19 samples of normal breast tissue was subjected to resequencing. No differences in CYP19 sequence were observed between tumor and germ-line DNA in the same patient. A total of 48 SNPs were identified including 4 novel SNPs when compared with previous resequencing data. For genotype-phenotype association studies, we determined the levels of aromatase activity, estrone, estradiol, and tumor size in patients pre-AI and post-AI treatment. We defined two tightly linked SNPs (rs6493497 and rs7176005 in the 5'-flanking region of CYP19 exon 1.1) that were significantly associated with a greater change in aromatase activity after AI treatment. In a follow-up study of 200 women with early-stage breast cancer who were treated with adjuvant anastrozole, these same two SNPs were also associated with higher plasma estradiol levels in patients pre-AI and post-AI treatment. Electrophoretic mobility shift and reporter gene assays confirmed likely functional effects of these two SNPs on transcription of CYP19. Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors. Cancer Res; 70(1); 319–28Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Haploview: analysis and visualization of LD and haplotype mapsBioinformatics, 2004
- CYP1B1 and CYP19 gene polymorphisms and breast cancer incidence: no association in the ARIC studyCancer Letters, 2004
- Score Tests for Association between Traits and Haplotypes when Linkage Phase Is AmbiguousThe American Journal of Human Genetics, 2002
- Polymorphism of the Aromatase Gene in Postmenopausal Italian Women: Distribution and Correlation with Bone Mass and Fracture RiskThe Journal of Clinical Endocrinology & Metabolism, 2001
- A tetranucleotide repeat polymorphism inCYP19 and breast cancer riskInternational Journal of Cancer, 2000
- Genetic variants of CYP19 (aromatase) and breast cancer riskOncogene, 2000
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Quasi-likelihood functions, generalized linear models, and the Gauss—Newton methodBiometrika, 1974